Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Shareholder Meeting (September 2025)
28 slides from Poly Medicure's shareholder meeting presentation, Sep 25, 2025
Slide 1: Welcome to the 30th Annual General Meeting
Welcome to the 30th Annual General Meeting Poly Medicure Ltd. 25th September 2025
Slide 2: Forward Looking Statement
Forward Looking Statement Disclaimer This presentation has been prepared for general information purposes in respect of Poly Medicure Limited (“Company”) together with any subsidiary, associate or joint venture, as applicable (together, with the Company, the “Group”) only, without regard to any spec
Slide 3: Key Highlights of the year
Key Highlights of the year Acquisition of Citieffe Inc Acquisition of RisoR Stent Clinical Study PendraCare Group Acquiring 100% stake in India’s First International Acquired 90% stake in the Italy-based Citieffe Inc. Netherlands-based Clinical registry of 2000 which manufactures PendraCare Group wh
Slide 4: Citieffe – fully integrated Trauma and Extremity supplier with global sales footprint
Citieffe – fully integrated Trauma and Extremity supplier with global sales footprint Vertically integrated developer, manufacturer and distributor of Trauma and Extremity fixation systems … Citieffe With diversified revenue base Backed by strong management Core Business Split, CY24 Founded in 1962,
Slide 5: Manufacturing Facility Overview
Manufacturing Facility Overview Facility overview FISA cleaning machine IEMCA Bar Feeders Milling Machine: Vesta 610D Laser Marking LASIT Blasting Machine Turning Machine: Compact mark G7 NORDBLAST TORNOS Deco EVO20 ISO 9001 & ISO 13485 approved manufacturing 2 production facilities: Bologna, Italy
Slide 6: Citieffe product portfolio, powered by strong R&D and globally accredited quality
Citieffe product portfolio, powered by strong R&D and globally accredited quality Products Areas Covered by Portfolio Products Category Humerus Internal Radius Fixators Ulna Femur 3 External Fixators Tibia Navigation Systems and Instruments Made in Italy 6
Slide 7: PendraCare – A Unique Interventional Cardiology consumable business in Europe
PendraCare – A Unique Interventional Cardiology consumable business in Europe PendraCare – One-of-a-kind opportunity With diversified revenue base Backed by strong management Core Business Split, CY24 Sander Hartman – Located in Leek Netherlands CEO / Founder Guiding In Pendracare since 2012 Product
Slide 8: Manufacturing Facility Overview
Manufacturing Facility Overview Leek, Netherlands ISO 13485 and FDA approved manufacturing 3,800 m2 Leased facility (across 3 locations) 1,150 m2 Cleanroom >1.5 million production capacity per year New lease signed ~2300m2 for consolidating operations at one location; transition expected in CY 2028
Slide 9: Well Established Products with regulatory approvals in key markets
Well Established Products with regulatory approvals in key markets Product Description Photos OEM Distributor • CE marked & FDA approved Guiding Catheter • 2.5-year ARCUS-IMPROVE clinical data (GC) • Radial access design: hydrophilic coating & support Diagnostic Catheter • CE marked (DC) • Superior
Slide 10: Ongoing work in Manufacturing Plant
Ongoing work in Manufacturing Plant Palwal plant is under construction and is expected to begin operation in FY26-27 Palwal, Haryana Palwal, Haryana In Haridwar plant work is in more advanced stage and is expected to begin operation in Q3’ FY25-26 Haridwar, Uttarakhand 10
Slide 11: Polymed at a Glance
Polymed at a Glance 12 13 Manufacturing Plants Specialities Across 5 countries 125+ Countries 200+ Medical Devices 3500+ Employee Base 530+ Sales Associates 334 Patents Granted 900+ 1.8 Billion+ Devices Manufacturing Capacity Distributors across India & Globally Per year 11
Slide 12: Recent Awards & Accolades
Recent Awards & Accolades Himanshu Baid, MD, Poly Medicure Himanshu Baid, MD, Poly Medicure Hurun India 2024 List of EY Entrepreneur of the Year Award 2024 - Healthcare Icon/Leader of the Year India's 500 Most Valuable Companies Lifesciences & Healthcare Category 2025 by ET Healthcare Awards Himansh
Slide 13: Navigating Our Journey
Navigating Our Journey Polymed’s Path of Milestones and Triumphs QIP 2 INR 1,000Cr raised QIP 1 INR 400Cr raised Cardiology & 2024 Critical Care PolyHealth Medical 2021 (US subsidiary of Poly Medicure ) 2019 2016 2011 2003 2007 2025 Acquired Company New R&D Plan1 Health, Joint Venture in Haridwar li
Slide 14: 13 Plants: Polymed's Manufacturing Footprint
Polymed's Manufacturing Footprint 13 Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India SEZ 2, Jaipur, India Laiyang-qingdao, 104-105,Faridabad Amaro, Italy Haridwar Plant, India IMT 2, Faridabad 115-116, Faridabad SEZ 1 Jaipur, India R & D Centre, India Assuit, Egypt China P
Slide 15: Mastering Manufacturing
Mastering Manufacturing Striving Towards Operational Excellence 15
Slide 16: Diving into our Product Portfolio
Diving into our Product Portfolio Vascular Access Disinfecting Pre-filled Saline Syringe Central Venous Safety Introducer Safety Winged IV Cannula Cap IV Sets Three Way Stop Cock Infusion Set Catheters Needle Infusion Therapy Extension Lines with Infusion Set with Three Way Stop Cock Arterial Blood
Slide 17: Cardiology, Surgery and Wound
Cardiology Diagnostic Catheter PTCA Balloon PTCA Balloon DES Hydrophilic Guidewire PTFE Coated Guidewire Dilation Catheter SC Dilation Catheter NC Guiding Catheter Closed Wound Surgery and Suction Unit Wound Drainage Closed Wound Centesis Catheter High Pressure Redon Under Water Thoracic Yankauer Ya
Slide 18: Recent key new products launches
Recent key new products launches Critical Care Cardiology PTCA Balloon Guiding Introducer Manifold Midline Catheter Umbilical Catheter Surfactant Catheter Drug Eluting Dilatation Catheter Catheter Needle (2port/3Port) Stent (SC/NC) Medicated Central Diagnostic Hydrophilic PTFE Coated Inflation Devic
Slide 19: India MedTech – Sunrise Sector Unveiling Enormous Growth Opportunities
India MedTech – Sunrise Sector Unveiling Enormous Growth Opportunities 4th $15 Bn 15-20% CAGR Growth $50 Bn Largest Market in Asia Current Market Size Historic Growth - Projected Growth Market Size by 2035 After Japan, China & South 2009: 1B→2015:2B→2015:4B → Korea 2022: $11B Evolving Ecosystem Demo
Slide 20: Our Strength: Consistent all-round growth
Our Strength: Consistent all-round growth ₹ REVENUE (₹ Crs) EBIDTA (₹ Crs) 2,000.0 600.0 CAGR 22.4% 1,669.8 CAGR 34.1% 542.0 1,600.0 1,375.8 480.0 416.5 1,200.0 1,115.2 360.0 301.6 800.0 240.0 400.0 120.0 - - FY 2023 FY 2024 FY 2025 FY 2023 FY 2024 FY 2025 ₹ PBT (₹ Crs) ₹ PAT (₹ Crs) 500.0 452.5 400
Slide 21: Standalone Sales Financial Performance Analysis
Standalone Sales Financial Performance Analysis Figs in Rs. Crs unless specified Particulars FY 25 FY 24 Growth % Domestic Revenue 486.4 410.0 18.6% International Revenue 1,102.9 889.4 24.0% Other Operating Revenue 12.6 7.9 59.8% Total Operating Revenue 1,601.8 1,307.2 22.5% Geographical Revenue Mix
Slide 22: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Particulars FY 25 FY 24 Growth % Infusion Therapy 1,013.6 860.4 17.8% Renal 151.3 94.5 60.1% Others 436.9 352.4 24.0% Total Operating Revenue 1,601.8 1307.2 22.5% Revenue Mix by Segment 100% 27% 27% 80% 9% 7% 60% 40% 63% 66% 20
Slide 23: Balance Sheet
Balance Sheet Figs in Rs. Crs unless specified Standalone Consolidated Particulars As at March 31, 2025 As at March 31, 2024 As at March 31, 2025 As at March 31, 2024 Total Shareholders Funds 2,744.2 1,458.2 2,765.7 1,470.1 Equity Share Capital 50.7 48.0 50.7 48.0 Other Equity 2,693.6 1,410.3 2,715.
Slide 24: Return Ratios
Return Ratios ROCE1 ROE2 19% 21% 15% 16% 17% 15% FY 23 FY 24 FY 25 FY 23 FY 24 FY 25 1 Return on Capital Employed (RoCE) calculated as Earning before interest and taxes (EBIT) / (Capital Employed (Shareholder's Equity + Total Debt + Deferred Tax Liability) 2 Return on Equity (RoE) calculated as Prof
Slide 25: Shareholding Pattern as of 31st August 2025
Shareholding Pattern as of 31st August 2025 Others 14.2% Insurance FPI Companies 10.6% 2.8% AIF Promoter and 2.5% Promoter Group 62.4% Mutual Funds 7.5% 25
Slide 26: Way Forward
Way Forward Research & Development Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations Emphasizing Inorganic Growth Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expanding market reac
Slide 27: Sustainable Development
Towards our Commitment to a Sustainable World Approx. 50% facilities are certified under Achieved ~4% reduction in Scope 2 ISO 14001:2015 during APR-AUG 25 compared to the same ENVIRONMENTAL period in FY 24-25 MANAGEMENT SYSTEM SCOPE 2 EMISSION Annual Health check-up of 208 employees APR TO AUG 25
Slide 28: Thank You
Poly Medicure Limited Registered Office: Thank You 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com